Borowitz, Drucy
Lubarsky, Barry
Wilschanski, Michael
Munck, Anne
Gelfond, Daniel
Bodewes, Frank
Schwarzenberg, Sarah Jane
Funding for this research was provided by:
Cystic Fibrosis Foundation Therapeutics, Inc. (BOROWI03CS0)
National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK095738-01)
Article History
Received: 15 May 2015
Accepted: 29 July 2015
First Online: 7 August 2015
Compliance with Ethical Standards
:
: Barry Lubarsky is an employee of Vertex Pharmaceuticals Incorporated and may own stock or stock options in the company.
: No honoraria or other forms of payment were made for authorship of this article. Editorial assistance for this manuscript was provided by Peloton Advantage, Parsippany, NJ, and was funded by Vertex Pharmaceuticals Incorporated.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. As this was a post hoc analysis, no formal patient consent is required.